Biofire: Upper and Lower Respiratory Panel, Meningitis Panel and Gastrointestinal Panel

BioFire® Syndromic Panels represent a revolutionary shift in diagnostic microbiology by using a "syndromic approach". Instead of testing for one pathogen at a time, these multiplex PCR tests simultaneously screen for a broad grouping of bacteria, viruses, and parasites that cause similar symptoms. This provides actionable results in approximately one hour, allowing for immediate clinical decisions.

1. BioFire® Respiratory 2.1 (RP2.1) Panel

This is the frontline "Upper Respiratory" panel designed to differentiate between COVID-19 and other common viruses.

• Pathogens (22 Targets): Includes SARS-CoV-2, Influenza A/B, RSV, Adenovirus, Parainfluenza, Human Metapneumovirus, Rhinovirus/Enterovirus, and Bordetella pertussis.
• Common Symptoms: Fever, persistent cough, runny nose, sore throat, and fatigue.
• Associated Diseases: COVID-19, the flu, common cold, whooping cough, and viral pharyngitis.
• Sample Type: Nasopharyngeal swab in transport media.
• Eligibility: Indicated for patients with moderate-to-severe respiratory symptoms where distinguishing the specific virus is critical for isolation or antiviral therapy.
• Benefit: Reduces unnecessary antibiotic use for viral infections and streamlines hospital "cohorting" and isolation protocols.

2. BioFire® Pneumonia (PN) Panel

Often referred to as the "Lower Respiratory" panel, this test is specifically optimized for severe lung infections.

• Pathogens (33 Targets): Includes 18 bacteria (many reported semi-quantitatively to distinguish colonization from infection), 8 viruses, 3 atypical bacteria, and 7 antimicrobial resistance (AMR) genes (e.g., Carbapenemases, MRSA markers).
• Common Symptoms: High fever, productive cough (yellow/green phlegm), shortness of breath (dyspnea), and chest pain.
• Associated Diseases: Community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and bronchiectasis exacerbations.
• Sample Type: Sputum, endotracheal aspirate, or bronchoalveolar lavage (BAL).
• Eligibility: Primarily used for hospitalized or critically ill patients, especially those on ventilators.
• Care Requirement: Clinical teams use the semi-quantitative results to "de-escalate" broad-spectrum antibiotics to more targeted therapy within hours of admission.

3. BioFire® Meningitis/Encephalitis (ME) Panel

This panel identifies the most common causes of central nervous system (CNS) infections that are often medical emergencies.

• Pathogens (14 Targets): 6 bacteria (e.g., S. pneumoniae, N. meningitidis), 7 viruses (e.g., HSV-1/2, Enterovirus, VZV), and 1 yeast (Cryptococcus).
• Common Symptoms: Severe headache, neck stiffness (nuchal rigidity), photophobia (light sensitivity), confusion, and fever.
• Associated Diseases: Bacterial meningitis, viral encephalitis, and meningoencephalitis.
• Sample Type: Cerebrospinal fluid (CSF) collected via lumbar puncture.
• Eligibility: Any patient presenting with signs of CNS inflammation, particularly children, the elderly, or immunocompromised individuals.
• Post-Care: Results often allow doctors to stop unnecessary Acyclovir or broad antibiotics if a non-target or viral cause (like Enterovirus) is found.

4. BioFire® Gastrointestinal (GI) Panel

This panel targets the most common pathogens associated with severe or persistent "stomach flu".

• Pathogens (22 Targets): 13 bacteria (e.g., Salmonella, C. difficile, E. coli O157), 5 viruses (e.g., Norovirus, Rotavirus), and 4 parasites (e.g., Giardia, Cryptosporidium).
• Common Symptoms: Severe diarrhea, bloody stools (dysentery), intense abdominal cramps, and signs of dehydration.
• Associated Diseases: Infectious gastroenteritis and foodborne illness outbreaks.
• Sample Type: Stool sample in Cary Blair transport medium.
• Eligibility: Recommended for patients with symptoms lasting $>7$ days, severe dehydration, or those in outbreak settings.
• Hospitalization Timeline: Patients tested with this panel often see a near 5-day reduction in hospital length of stay compared to traditional stool cultures.

Summary of 2026 Clinical Benefits

Disclaimer: As per the doctor’s advice, hospitalization or isolation protocols may be modified based on the specific pathogen detected and the patient's clinical stability.